Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Paused · Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.

Key facts

Study ID

NCT00004998

Run by

Agouron Pharmaceuticals

People needed

30

Starts

1999-11-01

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients may be eligible if they:
• Are HIV-positive.
• Are at least 18 years old.
• Have a CD4 cell count of more than 50 cells/mm3.
• Have an HIV level of more than 5000 copies/ml.

You may not qualify if…

• Patients will not be eligible if they:
• Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with the last dose taken more than 6 months prior to study entry.
• Have taken an experimental drug within 28 days of study entry.

Where it is running

• Clin Research of West Florida — Clearwater, Florida, United States
• Community Health Care — Fort Lauderdale, Florida, United States
• South Shore Hosp — Miami, Florida, United States
• Infectious Diseases Associates — Sarasota, Florida, United States
• AIDS Research Consortium of Atlanta — Atlanta, Georgia, United States
• Beth Israel Deaconess Med Ctr — Boston, Massachusetts, United States
• Catholic Med Ctr — Jamaica, New York, United States
• Liberty Medical — New York, New York, United States
• Anderson Clinical Research — Pittsburgh, Pennsylvania, United States
• Immunity Care and Research Inc — Santo Domingo, Dominican Republic

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.